밍크 테라퓨틱스INKT 주가

MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical Illness

First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteriaLandmark advances a first-in-class immune

MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.

We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...

MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic collaborations, while navigating financial hurdles and development risks.

♻️ 재탕MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript

MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call May 15, 2026 8:30 AM EDTCompany ParticipantsStefanie Perna-NacarJennifer Buell - Co-Founder, President,...

MiNK (INKT) Q4 2025 Earnings Call Transcript

Jennifer Buell: Thank you, Stefanie. For those new to MiNK Therapeutics, we are advancing a clinically validated allogeneic invariant natural killer T cell platform, one that is fundamentally differentiated in its ability to restore and coordinate immune function across diseases or even an immune failure. MiNK cells are now in Phase II clinical trials in patients with solid tumor cancers and autoimmune inflammatory conditions like GvHD and severe lung disease.

MiNK Therapeutics Q1 Earnings Call Highlights

MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial results that management s

MiNK Therapeutics (NASDAQ:INKT) Posts Narrower-Than-Expected Q1 Loss, Advances iNKT Therapy Into Pivotal Testing

MiNK Therapeutics (INKT) reports a narrower-than-expected Q1 loss of -$0.57/share, beating estimates. The biopharma advances agenT-797, its iNKT cell therapy, into a pivotal Phase 2 trial for acute lung injury.

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung diseaseNon-dilutive collaborations expand MiNK’s platform and potentiate meaningful commercial revenue potential, while preserving focus on lead clinical programsCompany continues disciplined execution with reduced op